Transient reactivation of Epstein-Barr virus in non chronically immunosupressed patients undergoing a short treatment with a humanized non mitogenic CD3 antibody
Bart Keymeulen(Vrije Universiteit Brussel), Lucienne Chatenoud(Hôpital Necker-Enfants Malades), Michel Goldman(Université Libre de Bruxelles), Denis Piérard(Vrije Universiteit Brussel), Laurent Crenier(Université Libre de Bruxelles), Jean‐Marie Seigneurin(Centre National de la Recherche Scientifique), Sophie Candon, Chantal Mathieu(KU Leuven), Daniël Pipeleers(Vrije Universiteit Brussel), Melanie Walter(The University of Sydney), Herman Waldmann(University of Cambridge), J F. Bach, G Hale(Union Bank of Switzerland), A. Ziegler, Evy Vandemeulebroucke(Center for Beta Cell Therapy in Diabetes)
VUBIR (Vrije Universiteit Brussel)
January 1, 2006
Cited by 0
Related Papers
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
|Diabetes Care|2022|1.9k
Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
|Diabetologia|2022|986
Multicenter Evaluation of a Sequence-Based Protocol for Subtyping Shiga Toxins and Standardizing Stx Nomenclature
|Journal of Clinical Microbiology|2012|828
Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans
|Journal of Clinical Investigation|2010|516